Evidence map›Paper›PMID 41784079›Full record

ArticleClinical pharmacology in drug development2026

Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of [

Annick Menetrey, Valérie Nicolas-Metral, Marie-Claude Roubaudi-Fraschini, Tri Tat, Yuan Zhao, Yulia Vugmeyster, Karthik Venkatakrishnan, Felix Rohdich, Holger Scheible

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology in drug development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Annick MenetreyDebiopharm International SA, Lausanne, Switzerland.
Valérie Nicolas-MetralDebiopharm International SA, Lausanne, Switzerland.
Marie-Claude Roubaudi-FraschiniDebiopharm International SA, Lausanne, Switzerland.
Tri TatDebiopharm International SA, Lausanne, Switzerland.
Yuan ZhaoQuantitative Pharmacology, EMD Serono Research and Development Institute, Inc. Merck KGaA, Billerica MA, USA, Darmstadt, Germany.
Yulia VugmeysterQuantitative Pharmacology, EMD Serono Research and Development Institute, Inc. Merck KGaA, Billerica MA, USA, Darmstadt, Germany.
Karthik VenkatakrishnanQuantitative Pharmacology, EMD Serono Research and Development Institute, Inc. Merck KGaA, Billerica MA, USA, Darmstadt, Germany.
Felix RohdichNCE DMPK, Merck Healthcare KGaA, Darmstadt, Germany.
Holger ScheibleNCE DMPK, Merck Healthcare KGaA, Darmstadt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This Phase 1, open-label, 2-part, single-dose study aimed to investigate the pharmacokinetics, metabolism, and excretion of xevinapant, a small molecule inhibitor of apoptosis proteins (IAPs), in healthy male subjects. Part 1 focused on determining the mass balance recovery, pharmacokinetics, and metabolic profile of [

Indexed as

Inhibitor of Apoptosis ProteinsAdministration, OralAdultBiological AvailabilityCarbon RadioisotopesHalf-LifeHealthy VolunteersHumansMaleTissue DistributionYoung AdultCarbon RadioisotopesInhibitor of Apoptosis Proteinsabsolute bioavailabilityADMEhealthy volunteersmass balancemicrotracerpharmacokineticsxevinapant

Identifiers

PMID41784079
PMCPMC12961726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.